The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization
Open accessAbstract
A pharmacokinetic-pharmacodynamic (PKPD) model that characterizes the full time course of in vitro time-kill curve experiments of antibacterial drugs was here evaluated in its capacity to predict the previously determined PK/PD indices. Six drugs (benzylpenicillin, cefuroxime, erythromycin, gentamicin, moxifloxacin, and vancomycin), representing a broad selection of mechanisms of action and PK and PD characteristics, were investigated. For each drug, a dose fractionation study was simulated, using a wide range of total daily doses given as intermittent doses (dosing intervals of 4, 8, 12, or 24 h) or as a constant drug exposure. The time course of the drug concentration (PK model) as well as the bacterial response to drug exposure ( in vitro PKPD model) was predicted. Nonlinear least-squares regression analyses determined the PK/PD index (the maximal unbound drug concentration [ fC max ]/MIC, the area under the unbound drug concentration-time curve [ f AUC]/MIC, or the percentage of a 24-h time period that the unbound drug concentration exceeds the MIC [ fT >MIC ]) that was most predictive of the effect. The in silico predictions based on the in vitro PKPD model identified the previously determined PK/PD indices, with fT >MIC being the best predictor of the effect for β-lactams and f AUC/MIC being the best predictor for the four remaining evaluated drugs. The selection and magnitude of the PK/PD index were, however, shown to be sensitive to differences in PK in subpopulations, uncertainty in MICs, and investigated dosing intervals. In comparison with the use of the PK/PD indices, a model-based approach, where the full time course of effect can be predicted, has a lower sensitivity to study design and allows for PK differences in subpopulations to be considered directly. This study supports the use of PKPD models built from in vitro time-kill curves in the development of optimal dosing regimens for antibacterial drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979253358 · Cited by 1,134
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Craig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Self-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100235 · Cited by 452
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Animal model pharmacokinetics and pharmacodynamics: a critical review
Andes, D., & Craig, W. A. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00022-5 · Cited by 413
Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380
Hyatt, J. M., McKinnon, P. S., Zimmer, G. S., & Schentag, J. J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00005 · Cited by 374
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens
Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., & Levin, B. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3670-3676.2004 · Cited by 332
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
DANHOF, M., DELANGE, E., DELLAPASQUA, O., PLOEGER, B., & VOSKUYL, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.007 · Cited by 287
Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
Craig, W. A., Redington, J., & Ebert, S. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.suppl_c.29 · Cited by 238
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16814 · Cited by 238
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316814 · Cited by 236
Eagle, H., Fleischman, R., & Levy, M. (1953) · New England Journal of Medicine · doi:10.1056/nejm195303192481201 · Cited by 230
Lacy, M. K., Lu, W., Xu, X., Tessier, P. R., Nicolau, D. P., Quintiliani, R., & Nightingale, C. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.672 · Cited by 219
Pharmacodynamics and dosing of aminoglycosides
Turnidge, J. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00057-6 · Cited by 192
Adaptive Resistance to Aminoglycoside Antibiotics from First-Exposure Down-Regulation
Daikos, G. L., Jackson, G. G., Lolans, V. T., & Livermore, D. M. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.2.414 · Cited by 181
Nielsen, E. I., Viberg, A., Löwdin, E., Cars, O., Karlsson, M. O., & Sandström, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00604-06 · Cited by 172
Self-citationDaikos, G. L., Lolans, V. T., & Jackson, G. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.117 · Cited by 163
Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models
Andes, D. R., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1665-1670.2002 · Cited by 153
Mouton, J. W., Vinks, A. A. T. M. M., & Punt, N. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.733 · Cited by 142
Population Pharmacokinetics of Vancomycin in Japanese Pediatric Patients
Yasuhara, M., Iga, T., ZENDA, H., Okumura, K., Oguma, T., Yano, Y., & Hori, R. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199812000-00005 · Cited by 141
Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects
Czock, D., & Keller, F. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9069-x · Cited by 134
Bradley, J. S., Dudley, M. N., & Drusano, G. L. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000094940.81959.14 · Cited by 122
In vitro pharmacodynamic models to determine the effect of antibacterial drugs
Gloede, J., Scheerans, C., Derendorf, H., & Kloft, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp434 · Cited by 112
Bulitta, J. B., Ly, N. S., Yang, J. C., Forrest, A., Jusko, W. J., & Tsuji, B. T. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00489-08 · Cited by 98
Frimodt-Meller, N., Bentzen, M. W., & Thomsen, V. F. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/154.3.511 · Cited by 88
Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates
Nielsen, E. I., Sandström, M., Honoré, P. H., Ewald, U., & Friberg, L. E. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948040-00003 · Cited by 80
Self-citationMouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-06 · Cited by 80
Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141
Mouton, J. W., Schmitt‐Hoffmann, A. H., Shapiro, S., Nashed, N., & Punt, N. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1713-1718.2004 · Cited by 78
Barbour, A., Scaglione, F., & Derendorf, H. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.023 · Cited by 68
Patel, N., Scheetz, M. H., Drusano, G. L., & Lodise, T. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-09 · Cited by 66
Gustafsson, I., Löwdin, E., Odenholt, I., & Cars, O. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2436-2440.2001 · Cited by 65
Self-citationZhi, J., Nightingale, C. H., & Quintiliani, R. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751108 · Cited by 56
Tam, V. H., Ledesma, K. R., Vo, G., Kabbara, S., Lim, T.-P., & Nikolaou, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-07 · Cited by 53
AUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval
Schentag, J. J., Nix, D. E., Forrest, A., & Adelman, M. H. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000920 · Cited by 48
Nielsen, E. I., Cars, O., & Friberg, L. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01286-10 · Cited by 44
Self-citationTam, V. H., & Nikolaou, M. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001043 · Cited by 39
Netilmicin and gentamicin multidose kinetics in normal subjects
Laskin, O. L., Longstreth, J. A., Smith, C. R., & Lietman, P. S. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.227 · Cited by 35
“Getting the Dose Right”: Facts, a Blueprint, and Encouragements
Peck, C. C., & Cross, J. T. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100215 · Cited by 33
Marshall, S. F., Macintyre, F., James, I., Krams, M., & Jonsson, E. N. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00004 · Cited by 32
Katsube, T., Yano, Y., Yamano, Y., Munekage, T., Kuroda, N., & Takano, M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21265 · Cited by 27
Cited by
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Self-citation
Metadata
- Authors
- Nielsen, E. I., Cars, O., & Friberg, L. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-10
- Volume
- 55
- Issue
- 10
- Pages
- 4619-4630
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2137928929
- Cited by
- 254
- References
- 55
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.